



## **AbolerIS Pharma is one of the laureates of the 23rd edition of the i-Lab innovation contest 2021.**

**Nantes, France, September 08, 2021** – AbolerIS Pharma is a pre-clinical stage biotech company specialized in the development of innovative immunomodulators for the treatment of transplant rejection, graft-versus-host-disease and auto-immune diseases.

The company announces that it has been rewarded as one of the laureates at the 23<sup>rd</sup> national i-Lab innovation competition. This prestigious and highly competitive national contest supports the best projects for new innovative technology companies. The competition is organized by the French Ministry of Research in partnership with BPI France. Laureate companies receive a significant financial non-dilutive support and are eligible to further financial support from BPI France.

Dr. Ann Meulemans, CEO of AbolerIS Pharma comments: “We are very proud to be selected out of hundreds of projects by a national jury of experts. This prize is a perfect match with our ambitions, as i-Lab aims to support start-ups that address major social and medical challenges. The granted funding will contribute to the development of our lead anti-CD45RC monoclonal antibody, in a range of indications with high unmet need.”

### **About AbolerIS Pharma ([www.aboleris-pharma.com](http://www.aboleris-pharma.com))**

Founded in November 2019 by Dr. Carole Guillonnet (Director of Research CNRS) and Dr. Ignacio Anegón (Director of Research INSERM), researchers in Unit 1064-CRTI INSERM University of Nantes, located at the Nantes University Hospital, together with Dr. François-Xavier Hubert, MD PhD. AbolerIS Pharma is developing two innovative strategies to regulate the immune system: an anti-CD45RC monoclonal antibody and the cytokine IL-34. In October 2020, AbolerIS Pharma raised €2.5 million from an investment consortium comprised of Turenne Santé/Sham Innovation Santé and Newton Biocapital and obtained an exclusive worldwide license by Ouest Valorisation, a French TTO.

For more information:

Ann Meulemans, PhD

[Ann.meulemans@aboleris-pharma.com](mailto:Ann.meulemans@aboleris-pharma.com)